Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: An open-label, multicentre, randomized phase IIIb trial

Drugs and Aging

Volumn 30, Issue 10, 2013, Pages 829-836

  Konychev, Alexander ^a   Heep, Markus ^b   Moritz, Rose K C ^c   Kreuter, Alexander ^c   Shulutko, Alexander ^d   Fierlbeck, Gerhard ^e   Bouylout, Kamel ^b   Pathan, Rashidkhan ^f   Trostmann, Uwe ^b   Chaves, Ricardo L ^b  

^a City Oncology Center   (Russian Federation)

^b NOVARTIS PHARMA AG   (Switzerland)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f Novartis Pharmaceuticals Corporation   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLOXACILLIN; DAPTOMYCIN; FLUCLOXACILLIN; OXACILLIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AGED; ANTIBIOTIC THERAPY; CELLULITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DECUBITUS; DIABETIC FOOT; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPERTHERMIA; HYPOGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY; NAUSEA; NECROSIS; NEPHROTOXICITY; OPEN STUDY; OUTCOME ASSESSMENT; PANCYTOPENIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN ABSCESS; SKIN ULCER; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; WOUND INFECTION;

AGED; DAPTOMYCIN; FEMALE; HUMANS; MALE; PATIENT SAFETY; SKIN DISEASES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890142748     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0114-8     Document Type: Review

References (14)

1. Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis. 2003;37(11):1453-60. (Pubitemid 37494672)
2. McClelland RS, Fowler VG Jr, Sanders LL, et al. Staphylococcus aureus bacteremia among elderly vs younger adult patients: comparison of clinical features and mortality. Arch Intern Med. 1999;159(11):1244-7. (Pubitemid 29269865)
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Diabetes Care. 2004;27(5):1047-53. (Pubitemid 38579764)
4. Pather M. The prevalence of renal impairment in the elderly hospitalized population. Int J Gen Med. 2009;2(1):117-9.
5. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8(1):117. (Pubitemid 351678123)
6. Sader HS, Farrell DJ, Jones RN. Antimicrobial activity of daptomycin tested against Gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009). J Chemother. 2011;23(4):200-6.
7. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673-81. (Pubitemid 38781657)
8. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653-65.
9. Gollnick H, Fierlbeck G, Seaton RA, et al. Efficacy and safety of daptomycin versus vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections: a multicentre, randomized, assessor-blind trial. In: 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria, 2012; Poster P1551.
10. ® (daptomycin): summary of product characteristics [online]. Horsham: United Kingdom, 2012. http://www.medicines.org.uk/emc/ medicine/17341. Accessed 20 Feb 2013.
11. Quist SR, Fierlbeck G, Seaton RA, et al. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections. Int J Antimicrob Agents. 2012;39(1):90-1.
12. EARSS management team. European Antimicrobial Resistance Surveillance System annual report 2011 [online]. 2011. http://ecdc.europa.eu/en/publications/ Publications/antimicrobial-resistance-surveillance-europe-2011.pdf. Accessed 4 Mar 2013.
13. Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008;29(2):160-9. (Pubitemid 351269212)
14. Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin. 2006;22(12):2337-43. (Pubitemid 46048350)